Clinical outcome and safety of rituximab therapy for pemphigoid diseases - 14/04/20
Doi : 10.1016/j.jaad.2019.11.023
Napatra Tovanabutra, MD a, b, Aimee S. Payne, MD, PhD a, ⁎ 
a Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
b Department of Internal Medicine, Division of Dermatology, Chiang Mai University, Chiang Mai, Thailand
∗Correspondence to: Aimee S. Payne, MD, PhD, University of Pennsylvania, 421 Curie Blvd, 1009 Biomedical Research Bldg, Philadelphia, PA 19104University of Pennsylvania421 Curie Blvd, 1009 Biomedical Research BldgPhiladelphiaPA19104
| Funding sources: Supported by the Faculty of Medicine, Chiang Mai University, Thailand. |
|
| Conflicts of interest: Dr Payne is a co-founder and equity holder in Cabaletta Bio, Inc, focused on targeted immunotherapy of pemphigus. She is an inventor on patents licensed by Novartis and Cabaletta Bio for cellular immunotherapy of autoimmune diseases and has previously served as a consultant for Syntimmune, Inc. These organizations had no involvement in the research reported in this study. Dr Tovanabutra has no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 5
P. 1237-1239 - mai 2020 Retour au numéro
Article précédent
- Diabetes mellitus and hyperglycemic complications in bullous pemphigoid
- Zi Teng Chai, Colin Tan, May MeiQi Liau, Harsharon Kaur, Shiu Ming Pang, Yee Wei Phoon, Nisha Suyien Chandran, Haur Yueh Lee
- Hidradenitis suppurativa encounters in a national electronic health record database notable for low dermatology utilization, infrequent biologic prescriptions, and frequent opiate prescriptions
- Mackenzie R. Wehner, Robert Micheletti, Megan H. Noe, Eleni Linos, David J. Margolis, Haley B. Naik
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?